Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (12282)	7/30/1998 12:33:00 AM
From: Mark A. Stang	Read Replies (1) \| Respond to of 23519

BigK, thanks for the article, validates being long VVUS. $250M is the criterion? Well VVUS did $100M with scant resources. Don't you think Big Pharma thinks they can do better, especially with Muse2 and later enhancements? ED is hot area. Even Ivax is working on an ED product. Viagra the Goliath is looking more vulnerable every passing week. The plaintiff's trial lawyers have their knives drawn. I would be interested to know specific examples of Big Pharma spin-offs. Bet you can't come up with one remotely analogous to Muse. Thanks again.